BRIEF — Pharnext's PXT3003 gets priority review for Charcot-Marie-Tooth Type 1A disease from China FDA

France-based Pharnext has announced that PXT3003 has been granted priority review for Charcot-Marie-Tooth Type 1A disease (CMT1A) by the China Food and Drug Administration (CFDA).

This drug is currently in a Phase III clinical trial in Europe and the USA, with results expected before the end of 2018, having been developed using Pharnext’s R&D platform.

It is a novel oral fixed-low dose combination of baclofen, naltrexone and sorbitol, with orphan drug designation from the US Food and Drug Administration and European Medicines Agency.